We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+27.1%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$168M
AUM Growth
+$5.88M
Cap. Flow
-$6.82M
Cap. Flow %
-4.05%
Top 10 Hldgs %
44.13%
Holding
98
New
36
Increased
11
Reduced
15
Closed
33

Top Buys

1
AMAG
AMAG Pharmaceuticals
AMAG
+$4.08M
2
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$2.7M
3
MMSI icon
Merit Medical Systems
MMSI
+$2.6M
4
CHTP
CHELSEA THERAPEUTICS INT'L LTD
CHTP
+$2.51M
5
HSTO
Histogen Inc. Common Stock
HSTO
+$2.3M

Top Sells

1
GILD icon
Gilead Sciences
GILD
+$10.6M
2
CBST
CUBIST PHARMACEUTICALS INC
CBST
+$3.44M
3
SPNC
Spectranetics Corp
SPNC
+$3.42M
4
MZOR
Mazor Robotics Ltd.
MZOR
+$3.42M
5
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$3.34M

Sector Composition

1 Healthcare 44.95%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OEF icon
1
PUT
iShares S&P 100 ETF
OEF
$20.1B
$17.5M 10.36%
+150,000
New +$12.2M
MRK icon
2
CALL
Merck
MRK
$315B
$14.2M 8.43%
+262,000
New +$13.6M
TEVA icon
3
CALL
Teva Pharmaceuticals
TEVA
$37.3B
$7.93M 4.71%
150,000
+50,000
+50% +$2.31M
GILD icon
4
CALL
Gilead Sciences
GILD
$167B
$7.09M 4.21%
100,000
– –
BMY icon
5
CALL
Bristol-Myers Squibb
BMY
$124B
$5.2M 3.08%
+100,000
New +$5.32M
VTRS icon
6
CALL
Viatris
VTRS
$20.1B
$4.88M 2.9%
+100,000
New +$4.86M
AEGR
7
CALL
DELISTED
Aegerion Pharmaceuticals
AEGR
$4.62M 2.74%
+100,000
New +$5.86M
VRTX icon
8
CALL
Vertex Pharmaceuticals
VRTX
$123B
$4.6M 2.73%
65,000
– –
PRTA icon
9
Prothena Corp
PRTA
$453M
$4.21M 2.5%
110,000
-20,000
-15% -$645K
BMY icon
10
Bristol-Myers Squibb
BMY
$124B
$4.16M 2.47%
80,000
-20,000
-20% -$1.06M
AVDL
11
DELISTED
Avadel Pharmaceuticals
AVDL
$4.02M 2.39%
300,000
+180,000
+150% +$1.93M
ARAY icon
12
Accuray
ARAY
$30.8M
$3.84M 2.28%
400,018
-49,982
-11% -$473K
INSM icon
13
CALL
Insmed
INSM
$23.5B
$3.81M 2.26%
+200,000
New +$3.8M
AMAG
14
DELISTED
AMAG Pharmaceuticals
AMAG
$3.72M 2.21%
+192,057
New +$4.08M
CHTP
15
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$3.31M 1.97%
600,000
+500,000
+500% +$2.51M
UNIS
16
DELISTED
Unilife Corporation
UNIS
$3.26M 1.93%
80,000
+45,000
+129% +$2.03M
CYH icon
17
Community Health Systems
CYH
$465M
$3.13M 1.86%
96,800
+12,100
+14% +$400K
ARWR icon
18
Arrowhead Research
ARWR
$10.5B
$3.04M 1.8%
185,000
-90,000
-33% -$1.58M
TRNX
19
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$2.76M 1.64%
130,000
+30,000
+30% +$582K
ICPT
20
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.64M 1.57%
+8,000
New +$2.7M
INSM icon
21
Insmed
INSM
$23.5B
$2.57M 1.53%
135,000
-65,000
-33% -$1.24M
TNDM icon
22
Tandem Diabetes Care
TNDM
$1.17B
$2.54M 1.51%
11,500
+7,000
+156% +$1.78M
MMSI icon
23
Merit Medical Systems
MMSI
$4.41B
$2.5M 1.49%
+175,000
New +$2.6M
OCRX
24
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.48M 1.47%
235,000
+160,000
+213% +$2.29M
FURX
25
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$2.39M 1.42%
+27,500
New +$2.12M
1
2 3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q1 2014 Portfolio in Review

As of Q1 2014, Ghost Tree Capital held 98 positions worth $168M, up 3.6% from $163M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Ghost Tree Capital withdrew a net $6.82M in Q1 2014, closing 33 positions and reducing 15 holdings. Its most notable exit was Gilead Sciences, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 50% a quarter earlier, followed by Technology.

Against the trend, Ghost Tree Capital opened a new position in AMAG Pharmaceuticals worth $3.72M.

  • Ghost Tree Capital's largest Q1 2014 buy was AMAG Pharmaceuticals: 192,057 shares worth $3.72M.
  • Ghost Tree Capital added most to CHELSEA THERAPEUTICS INT'L LTD in Q1 2014, an estimated $2.51M increase.
  • Ghost Tree Capital's biggest Q1 2014 reduction was Spectranetics Corp, cutting an estimated $3.42M.
  • Ghost Tree Capital fully exited Gilead Sciences in Q1 2014, selling an estimated $10.6M.
  • Ghost Tree Capital's ten largest holdings make up 44% of its $168M portfolio in Q1 2014.
  • Ghost Tree Capital opened 36 new positions and closed 33 in Q1 2014.
  • Ghost Tree Capital's portfolio value rose 3.6% quarter-over-quarter to $168M.

Based on Ghost Tree Capital's 13F filing for Q1 2014, filed 15 May 2014.